| ²é¿´: 1906 | »Ø¸´: 8 | |||
iamzaneÖÁ×ðľ³æ (ÖøÃûдÊÖ)
|
[½»Á÷]
¡¾ÌÖÂÛ¡¿ÒÁÂíÌæÄáºÍ¼ª·ÇÌæÄữºÏÎïרÀû
|
| ÕâÁ½¸öÒ©Îï¹úÄڵϝºÏÎïרÀûʲôʱºòµ½ÆÚ°¡£¿ÊÇÄöרÀû£¿ |
» ²ÂÄãϲ»¶
Çë½Ìõ£°·ËõºÏ·´Ó¦
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸´óÁ¬Àí¹¤ÖÆÒ©¹¤³Ìר˶086002£¬±¾¿Æ211£¬×Ü·Ö342
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ212È˻ظ´
ÖÆÒ©¹¤³ÌרҵÕÐÊÕµ÷¼Á£¬ÒªÇó¹ý¹ú¼ÒÏß
ÒѾÓÐ0È˻ظ´
ÎåÒØ´óѧҩÎﻯѧÉúÎïѧÍŶÓ-ÀîÀ¼Çå¿ÎÌâ×éÕÐÊÕµ÷¼ÁѧÉú
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ2È˻ظ´
342Ò»Ö¾Ô¸´ó¹¤ÖÆÒ©×¨Ë¶£¬±¾¿Æ211£¬Çóµ÷¼Á
ÒѾÓÐ2È˻ظ´
AcsÔÓÖ¾JAFCͶ¸åÇóÖú
ÒѾÓÐ4È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
¸÷λ¸ßÊÖ£¬¼×»ùºÍ¼×Ñõ»ùÔÚͬһ»¯ºÏÎïÖУ¬ºË´ÅÇâÆ×ÕâÑùÕý³£²»£¿
ÒѾÓÐ4È˻ظ´
зÖÀëµÄÒ»¸öÖ²Îïµ¥ÌåÄÜ·ñÉêÇ뻯ºÏÎïרÀû
ÒѾÓÐ13È˻ظ´
ÎÒ¹ú¡°ÌæÄáÀࡱ£¨ÀÒ°±ËἤøÒÖÖÆ¼Á£©¿¹Ö×ÁöÒ©µÄÊг¡ÏÖ×´
ÒѾÓÐ15È˻ظ´
л¯ºÏÎï·¢±íÎÄÕºÍÉêÇëרÀûµÄ¹ØÏµÌÖÂÛ
ÒѾÓÐ44È˻ظ´
¡¾ÇóÖú¡¿Õæ³ÏÇóÖúÒ©Æ·»¯ºÏÎïÔʼרÀûÔõô²éÕÒ£¿
ÒѾÓÐ50È˻ظ´
¡¾ÌÖÂÛ¡¿¼×»ÇËáÒÁÂíÌæÄáµÄ¸±×÷ÓÃ
ÒѾÓÐ14È˻ظ´
º¼ÖÝÕìÆÆÊ·ÉÏ×î´ó¼ÙÒ©°¸ ²©Ê¿ºóÀÏ×ÜÊǼÙÒ©··×Ó
ÒѾÓÐ13È˻ظ´
¡¾½»Á÷¡¿Ð¹Ǽܻ¯ºÏÎï רÀûÉêÇë
ÒѾÓÐ11È˻ظ´
¡¾×ªÌû¡¿¿¹Ö×ÁöÒ©ÎïµÄ·ÖÀàºÍÁÙ´²Ó¦ÓÃ
ÒѾÓÐ29È˻ظ´
qwliu
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 6 (Ó×¶ùÔ°)
- ½ð±Ò: 4802.3
- Ìû×Ó: 258
- ÔÚÏß: 68Сʱ
- ³æºÅ: 262477
- ×¢²á: 2006-06-25
- רҵ: ºÏ³ÉÒ©Îﻯѧ
¡ï
iamzane(½ð±Ò+2):thanks 2010-10-26 13:49:16
caoyuan521(½ð±Ò+1):лл²ÎÓ룡 2010-10-26 20:47:46
iamzane(½ð±Ò+2):thanks 2010-10-26 13:49:16
caoyuan521(½ð±Ò+1):лл²ÎÓ룡 2010-10-26 20:47:46
|
Ò©Îï»ù±¾ÐÅÏ¢ ·µ»Ø¼ìË÷½çÃæ ÏîÄ¿ ÐÅÏ¢ Ò©Æ·Ãû³Æ GLEEVEC ÉêÇëºÅ N021335 ²úÆ·ºÅ 001 »îÐÔ³É·Ö IMATINIB MESYLATE Êг¡×´Ì¬ DISCN ¼ÁÐÍ»ò¸øÒ©Í¾¾¶ CAPSULE; ORAL ¹æ¸ñ EQ 50MG BASE ¹Â¶ùÒ© ÊÇ ²Î±ÈÒ©Îï ·ñ Åú×¼ÈÕÆÚ 2001Äê05ÔÂ10ÈÕ ÉêÇë»ú¹¹ NOVARTIS »¯Ñ§ÀàÐÍ New molecular entity (NME) ÆÀÉó·ÖÀà Priority review drug FDAÉ걨×ÊÁÏ ÐÞ¶©ºÅ ÉóÅúÀàÐÍ ÉóÅú½áÂÛ ¹«¿ªÎĵµÀàÐÍ Îĵµ´´½¨Ê±¼ä ÎĵµÏÂÔØ 006 Labeling Revision AP Review 2004Äê09ÔÂ29ÈÕ PDF 003 Patient Population Altered AP Review 2004Äê08ÔÂ09ÈÕ PDF 004 New or Modified Indication AP Letter 2004Äê06ÔÂ04ÈÕ PDF 000 Approval AP Other Impo 2003Äê12ÔÂ09ÈÕ PDF 006 Labeling Revision AP Letter 2003Äê11ÔÂ25ÈÕ PDF 003 Patient Population Altered AP Letter 2003Äê07ÔÂ23ÈÕ PDF 001 New or Modified Indication AP Review 2003Äê07ÔÂ08ÈÕ PDF 004 New or Modified Indication AP Review 2003Äê07ÔÂ08ÈÕ PDF 003 Patient Population Altered AP Label 2003Äê05ÔÂ20ÈÕ PDF 002 Manufacturing Change or Addition AP Label 2003Äê04ÔÂ09ÈÕ PDF 004 New or Modified Indication AP Label 2002Äê12ÔÂ20ÈÕ PDF 001 New or Modified Indication AP Label 2002Äê02ÔÂ01ÈÕ PDF 001 New or Modified Indication AP Letter 2002Äê02ÔÂ01ÈÕ PDF 000 Approval AP Review 2001Äê05ÔÂ10ÈÕ PDF 000 Approval AP Label 2001Äê05ÔÂ10ÈÕ PDF 000 Approval AP Letter 2001Äê05ÔÂ10ÈÕ PDF Ò©ÎïרÀûÐÅÏ¢ רÀûºÅ רÀû¹ýÆÚÈÕ ÊÇ·ñ»¯ºÏÎïרÀû ÊÇ·ñ²úƷרÀû רÀûÓÃ;´úÂë רÀûÐÅÏ¢ 5521184 Jan 4, 2015 Y Y È«ÎÄÐÅÏ¢ 5521184*PED Jul 4, 2015 È«ÎÄÐÅÏ¢ 6894051 May 23, 2019 Y Y U-649 È«ÎÄÐÅÏ¢ 6894051*PED Nov 23, 2019 È«ÎÄÐÅÏ¢ 6958335 Dec 19, 2021 U-791 È«ÎÄÐÅÏ¢ 6958335*PED Jun 19, 2022 È«ÎÄÐÅÏ¢ Ò©ÎïÊг¡¶ÀռȨÐÅÏ¢ ¶ÀռȨ´úÂë ʧЧÈÕÆÚ ODE Feb 1, 2009 PED Aug 1, 2009 PED Nov 10, 2008 ÏîÄ¿ ÐÅÏ¢ Ò©Æ·Ãû³Æ IRESSA ÉêÇëºÅ N021399 ²úÆ·ºÅ 001 »îÐÔ³É·Ö GEFITINIB Êг¡×´Ì¬ RX ¼ÁÐÍ»ò¸øÒ©Í¾¾¶ TABLET; ORAL ¹æ¸ñ 250MG ¹Â¶ùÒ© ÊÇ ²Î±ÈÒ©Îï ·ñ Åú×¼ÈÕÆÚ 2003Äê05ÔÂ05ÈÕ ÉêÇë»ú¹¹ ASTRAZENEC »¯Ñ§ÀàÐÍ New molecular entity (NME) ÆÀÉó·ÖÀà Priority review drug FDAÉ걨×ÊÁÏ ÐÞ¶©ºÅ ÉóÅúÀàÐÍ ÉóÅú½áÂÛ ¹«¿ªÎĵµÀàÐÍ Îĵµ´´½¨Ê±¼ä ÎĵµÏÂÔØ 008 Labeling Revision AP Letter 2005Äê06ÔÂ21ÈÕ PDF 008 Labeling Revision AP Label 2005Äê06ÔÂ17ÈÕ PDF 005 Labeling Revision AP Letter 2004Äê12ÔÂ02ÈÕ PDF 000 Approval AP Letter 2004Äê06ÔÂ07ÈÕ PDF 003 Labeling Revision AP Letter 2004Äê05ÔÂ07ÈÕ PDF 003 Labeling Revision AP Label 2004Äê05ÔÂ07ÈÕ PDF 000 Approval AP Other Impo 2003Äê12ÔÂ09ÈÕ PDF 000 Approval AP Review 2003Äê07ÔÂ15ÈÕ PDF 000 Approval AP Label 2003Äê05ÔÂ05ÈÕ PDF Ò©ÎïרÀûÐÅÏ¢ רÀûºÅ רÀû¹ýÆÚÈÕ ÊÇ·ñ»¯ºÏÎïרÀû ÊÇ·ñ²úƷרÀû רÀûÓÃ;´úÂë רÀûÐÅÏ¢ 5457105 Jan 19, 2013 È«ÎÄÐÅÏ¢ 5616582 Jan 19, 2013 È«ÎÄÐÅÏ¢ 5770599 May 5, 2017 Y Y U-881 È«ÎÄÐÅÏ¢ Ò©ÎïÊг¡¶ÀռȨÐÅÏ¢ ¶ÀռȨ´úÂë ʧЧÈÕÆÚ ÎÞ ÎÞ |
2Â¥2010-10-26 13:36:55
iamzane
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 129 (¸ßÖÐÉú)
- ¹ó±ö: 0.7
- ½ð±Ò: 24671.1
- É¢½ð: 40
- ºì»¨: 21
- Ìû×Ó: 1974
- ÔÚÏß: 459.5Сʱ
- ³æºÅ: 330866
- ×¢²á: 2007-03-24
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
3Â¥2010-10-26 13:50:47
wpwill
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 1941.4
- Ìû×Ó: 314
- ÔÚÏß: 53.1Сʱ
- ³æºÅ: 116964
- ×¢²á: 2005-11-25
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
4Â¥2010-10-27 14:38:33
iamzane
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 129 (¸ßÖÐÉú)
- ¹ó±ö: 0.7
- ½ð±Ò: 24671.1
- É¢½ð: 40
- ºì»¨: 21
- Ìû×Ó: 1974
- ÔÚÏß: 459.5Сʱ
- ³æºÅ: 330866
- ×¢²á: 2007-03-24
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
5Â¥2010-10-27 15:48:10
hexinhua0920
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 32 (СѧÉú)
- ½ð±Ò: 4053.5
- É¢½ð: 160
- ºì»¨: 5
- Ìû×Ó: 898
- ÔÚÏß: 419.1Сʱ
- ³æºÅ: 235556
- ×¢²á: 2006-04-01
- ÐÔ±ð: GG
- רҵ: Ò©ÎïÉè¼ÆÓëÒ©ÎïÐÅÏ¢
¡ï
caoyuan521(½ð±Ò+1):лл²ÎÓ룡 2010-12-11 20:47:49
iamzane(½ð±Ò+1):3q 2010-12-13 10:13:06
caoyuan521(½ð±Ò+1):лл²ÎÓ룡 2010-12-11 20:47:49
iamzane(½ð±Ò+1):3q 2010-12-13 10:13:06
| ÕâÁ½¸öÆ·ÖÖÔÚÖйúרÀû¶¼Ã»ÓÐÊÚȨ°É£¬×¨ÀûÔÚ¹«¿ªÆÚÄÚ |
6Â¥2010-12-07 12:00:13
daijianfeng
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 459.4
- Ìû×Ó: 100
- ÔÚÏß: 10.4Сʱ
- ³æºÅ: 268434
- ×¢²á: 2006-07-29
- ÐÔ±ð: GG
- רҵ: ÖÐҩѧ

7Â¥2010-12-08 10:43:04
asymme
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1707.1
- ºì»¨: 3
- Ìû×Ó: 244
- ÔÚÏß: 69.9Сʱ
- ³æºÅ: 867483
- ×¢²á: 2009-10-10
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
¡ï
caoyuan521(½ð±Ò+1):лл²ÎÓ룡 2010-12-11 21:05:42
iamzane(½ð±Ò+1):3q 2010-12-13 10:13:19
caoyuan521(½ð±Ò+1):лл²ÎÓ룡 2010-12-11 21:05:42
iamzane(½ð±Ò+1):3q 2010-12-13 10:13:19
| Èç¹û¿ÉÒÔÉÏdialogµÄ»°£¬ÓÃIMSÊÀ½çÒ©ÎïרÀû¿ÉÒԺܷ½±ãµÄ²éѯרÀû¹ýÆÚʱ¼ä |
8Â¥2010-12-11 18:38:58
hexinhua0920
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 32 (СѧÉú)
- ½ð±Ò: 4053.5
- É¢½ð: 160
- ºì»¨: 5
- Ìû×Ó: 898
- ÔÚÏß: 419.1Сʱ
- ³æºÅ: 235556
- ×¢²á: 2006-04-01
- ÐÔ±ð: GG
- רҵ: Ò©ÎïÉè¼ÆÓëÒ©ÎïÐÅÏ¢
9Â¥2010-12-13 09:17:46














»Ø¸´´ËÂ¥